The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes

被引:12
作者
Adair, Sara J. [2 ]
Carr, Tiffany M. [2 ]
Fink, Mitsu J. [2 ]
Slingluff, Craig L., Jr. [2 ]
Hogan, Kevin T. [1 ,2 ]
机构
[1] Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA
[2] Univ Virginia, Human Immune Therapy Ctr, Dept Surg, Charlottesville, VA USA
关键词
cancer/testis antigen; CTL; epitope; immunotherapy;
D O I
10.1097/CJI.0b013e318159f797
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The TAG-1, TAG-2a, TAG-2b, and TAG-2c cancer/testis genes, known to be expressed in an unusually high percentage of melanoma cell lines, are shown here to be expressed in a variety of tumor lines of diverse histologic type, including cancers of the brain, breast, colon, lung, ovary, pharynx, and tongue. The genes are also expressed in fresh, uncultured melanoma, and ovarian cancer cells. Epitope prediction algorithms were used to identify potential HLA-A1, HLA-A2, HLA-A3, HLA-B7, and HLA-B8 epitopes, and these potential epitopes were tested for their ability to stimulate a peptide-specific cytotoxic T lymphocyte response using lymphocytes from healthy donors. Two HLA-A2-restricted epitopes (SLGWLFLLL and LLLRLECNV) were identified using this approach. Cytotoxic T lymphocytes specific for each of these peptides were capable of recognizing tumor cells expressing both the corresponding class I major histocompatibility complex encoded molecule and the TAG genes. These results indicate that TAG-derived peptides may be good components of a therapeutic vaccine designed to target melanoma and a variety of epithelial cell-derived malignancies.
引用
收藏
页码:7 / 17
页数:11
相关论文
共 34 条
  • [1] Castelli C, 2000, J CELL PHYSIOL, V182, P323, DOI 10.1002/(SICI)1097-4652(200003)182:3<323::AID-JCP2>3.0.CO
  • [2] 2-#
  • [3] A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
    Chen, YT
    Scanlan, MJ
    Sahin, U
    Tureci, O
    Gure, AO
    Tsang, SL
    Williamson, B
    Stockert, E
    Pfreundschuh, M
    Old, LJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) : 1914 - 1918
  • [4] Chomez P, 2001, CANCER RES, V61, P5544
  • [5] Human tumor-specific T lymphocytes: does function matter more than number?
    Coulie, PG
    Connerotte, T
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2005, 17 (03) : 320 - 325
  • [6] The three Es of cancer immunoediting
    Dunn, GP
    Old, LJ
    Schreiber, RD
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2004, 22 : 329 - 360
  • [7] A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use
    Feuerstein, B
    Berger, TG
    Maczek, C
    Röder, C
    Schreiner, D
    Hirsch, U
    Haendle, I
    Leisgang, W
    Glaser, A
    Kuss, O
    Diepgen, TL
    Schuler, G
    Schuler-Thurner, B
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2000, 245 (1-2) : 15 - 29
  • [8] GREENBERG PD, 1985, SURV IMMUNOL RES, V4, P283
  • [9] Hogan KT, 1998, CANCER RES, V58, P5144
  • [10] Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma
    Hogan, KT
    Coppola, MA
    Gatlin, CL
    Thompson, LW
    Shabanowitz, J
    Hunt, DF
    Engelhard, VH
    Ross, MM
    Slingluff, CL
    [J]. CANCER RESEARCH, 2004, 64 (03) : 1157 - 1163